Literature DB >> 18778448

Pervasive developmental disorder with attention deficit hyperactivity disorder-like symptoms and mismatch negativity.

Masayuki Sawada1, Hideki Negoro, Junzo Iida, Toshifumi Kishimoto.   

Abstract

The present study examined the correlation between the attention deficit hyperactivity disorder (ADHD) Rating Scale-IV Japanese version (ADHD RS-IV-J) score and mismatch negativity (MMN), in 10 pervasive developmental disorder (PDD) children with ADHD-like symptoms, and examined whether MMN become the objective measure to assess the severity of ADHD-like symptoms in PDD children. Consequently, score of ADHD RS-IV-J had a positive correlative tendency with MMN latency and had a significant strong negative correlation with MMN amplitude. Therefore, MMN may become an objective measure to assess the severity of ADHD-like symptoms in PDD children.

Entities:  

Mesh:

Year:  2008        PMID: 18778448     DOI: 10.1111/j.1440-1819.2008.01835.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  3 in total

1.  Associations between the mismatch-negativity component and symptom severity in children and adolescents with attention deficit/hyperactivity disorder.

Authors:  Kazuhiko Yamamuro; Toyosaku Ota; Junzo Iida; Yoko Nakanishi; Naoko Kishimoto; Toshifumi Kishimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-12       Impact factor: 2.570

2.  Associations between the Mismatch-negativity Potential and Symptom Severity in Medication-naïve Children and Adolescents with Symptoms of Attention Deficit/hyperactivity Disorder.

Authors:  Yeon Jung Lee; Mi Young Jeong; Jung Ho Kim; Ji-Sun Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-05-31       Impact factor: 2.582

3.  Deviance-Related Responses along the Auditory Hierarchy: Combined FFR, MLR and MMN Evidence.

Authors:  Tetsuya Shiga; Heike Althen; Miriam Cornella; Katarzyna Zarnowiec; Hirooki Yabe; Carles Escera
Journal:  PLoS One       Date:  2015-09-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.